Adaptive Biotechnologies (NASDAQ:ADPT) Shares Break Above 50 Day Moving Average Following Insider Selling

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares crossed above its 50 day moving average during trading on Wednesday following insider buying activity. The stock has a 50 day moving average of $26.37 and traded as high as $26.88. Adaptive Biotechnologies shares last traded at $26.71, with a volume of 2,326,040 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ADPT. BTIG Research increased their price objective on shares of Adaptive Biotechnologies from $25.00 to $34.00 and gave the company a “buy” rating in a research report on Tuesday, September 22nd. Guggenheim raised their target price on shares of Adaptive Biotechnologies from $25.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Piper Sandler lifted their target price on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. TD Cowen upped their price target on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. Finally, The Goldman Sachs Group assumed coverage on shares of Adaptive Biotechnologies in a report on Tuesday, September 29th. They issued a “buy” rating and a $35.00 price target on the stock. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.06.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive reported earnings of $0.02 per share, versus analysts’ expectation of a $0.10-per-share loss. Management also said the company achieved total-company profitability ahead of expectations. Third-quarter 2026 financial results
• Positive Sentiment: Revenue was $83.9 million, exceeding the $71.57 million analyst estimate. Core measurable residual disease (MRD) revenue grew 44%, a strong growth signal for a key business area. Q3 earnings and revenues top estimates
• Neutral Sentiment: COO Julie Rubinstein sold 11,881 shares under a pre-arranged Rule 10b5-1 trading plan and retained 377,802 shares. The planned nature of the sale may make it less meaningful as a signal about near-term business prospects. Insider share sale
• Negative Sentiment: Revenue was still down 10.7% from the year-ago quarter, tempering the strong results versus analyst estimates. The company also reported a negative net margin. Quarterly earnings report

Adaptive Biotechnologies Trading Up 3.5%

The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The business’s 50-day moving average is $26.37 and its 200 day moving average is $19.76. The firm has a market capitalization of $4.26 billion, a P/E ratio of -65.15 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.12. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $71.57 million. During the same quarter in the previous year, the firm posted $0.06 EPS. The business’s revenue for the quarter was down 10.7% compared to the same quarter last year. As a group, analysts anticipate that Adaptive Biotechnologies Corporation will post -0.40 EPS for the current fiscal year.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of hedge funds and other institutional investors have recently made changes to their positions in ADPT. University of Texas Texas AM Investment Management Co. acquired a new stake in Adaptive Biotechnologies during the third quarter worth approximately $277,000. Ethic Inc. acquired a new position in Adaptive Biotechnologies in the 3rd quarter valued at $244,000. Pictet Asset Management Holding SA raised its holdings in Adaptive Biotechnologies by 12.5% in the 3rd quarter. Pictet Asset Management Holding SA now owns 17,924 shares of the company’s stock valued at $518,000 after acquiring an additional 1,985 shares in the last quarter. Parr Mcknight Wealth Management Group LLC acquired a new position in Adaptive Biotechnologies in the 3rd quarter valued at $217,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Adaptive Biotechnologies during the 3rd quarter valued at $236,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.